PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Dec 2012 16:51

RNS Number : 5070T
Fastnet Oil & Gas PLC
13 December 2012
 



 

 

TR-1: Notifications of Major Interests in Shares

 

1: Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

FastNet Oil & Gas

 

2: Reason for notification (yes/no)

An acquisition or disposal of voting rights

no

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

no

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

no

An event changing the breakdown of voting rights

yes

Other (please specify):

 

no

 

3. Full name of person(s) subject to the notification

obligation:

 Standard Life Investments Ltd

4. Full name of shareholder(s) (if different from 3.):

 Vidacos Nominees

5. Date of the transaction (and date on which the threshold

is crossed or reached):

12/12/2012

6. Date on which issuer notified:

13/12/2012

7. Threshold(s) that is/are crossed or reached:

5%

 

 

 

8: Notified Details
A: Voting rights attached to shares
Class/type of share If possible use ISIN code
GB00B85HRF56
 
Situation previous to the triggering transaction
Number of shares
Number of voting rights
13,148,537
13,148,537
 
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Percentage ofvoting rights
Direct
Indirect
Direct
Indirect
13,148,537
6,425,000
6,723,537
2.345%
2.454%

 

 

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration date
Exercise/ conversion period/date
No. of voting rights that may be acquired(if the instrument exercised/converted)
Percentage of voting rights
 
 
 
 
 
 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

13,148,537

4.800%

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

 

14. Contact name:

 

investments_mo@standardlife.comStandard Life Investments Ltd

15. Contact telephone number:

 

(0131) 245 6565

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGMCPUPPGQW
Date   Source Headline
7th Jan 20197:00 amRNSPositive results for gene therapy AP103
4th Jan 201912:56 pmRNSEASE Phase III trial interim efficacy results
21st Dec 20182:05 pmRNSSecond Price Monitoring Extn
21st Dec 20182:00 pmRNSPrice Monitoring Extension
19th Dec 20187:00 amRNSUpdate on ongoing AP101 Trial
10th Dec 201811:30 amRNSGrant Funding from Irish Government for AP103
17th Oct 20187:00 amRNSLojuxta to be reimbursed in France
26th Sep 20187:00 amRNSInterim Results
14th Sep 20187:00 amRNSNotice of Results
10th Sep 20187:00 amRNSAmryt receives IND approval from FDA for AP101
2nd Aug 20187:00 amRNSFDA grants Pediatric Rare Disease designation
19th Jul 20187:00 amRNSTrading update & significant momentum building
9th Jul 20187:00 amRNSNHS England approves funding for Lojuxta
6th Jul 20187:00 amRNSChange of Registered Address
25th Jun 20188:10 amRNSCompany name alteration for previous release
25th Jun 20187:00 amRNSPositive data of Pollinex Quattro Grass vaccine
5th Jun 201810:41 amRNSResult of AGM
29th May 20187:00 amRNSFour Middle East Lojuxta® Distribution Agreements
10th May 20187:00 amRNSExclusive Lojuxta® Licence Expanded
9th May 20182:48 pmRNSHolding(s) in Company
8th May 20187:00 amRNSHolding(s) in Company and Lock-in agreement
4th May 20187:00 amRNSPosting of Annual Report 2017 and Notice of AGM
17th Apr 20187:00 amRNSFinal Results
15th Mar 20187:00 amRNSTrading update & Gene therapy agreement
6th Mar 20187:00 amRNSSenior Management Appointment
6th Mar 20187:00 amRNSDistribution Agreement for Lojuxta in Middle East
2nd Mar 20187:00 amRNSNotice of Trading Update
30th Jan 20187:00 amRNSNew Distribution Agreement Signed
24th Jan 20187:00 amRNSSenior Management Team Appointment
10th Jan 20187:00 amRNSNew Distribution Agreement Signed
8th Jan 20187:00 amRNSDistribution Agreement Signed Covering Switzerland
20th Dec 20177:00 amRNSSenior Management Team Appointment
1st Dec 20177:00 amRNSGrant of Options & PDMR Dealings
20th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSDistribution Agreement Signed in Saudi Arabia
13th Oct 20173:29 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirector Share Purchases
11th Oct 20177:00 amRNSHolding(s) in Company
11th Oct 20177:00 amRNSEnterprise Securities Market Notice
10th Oct 20177:00 amRNSEnterprise Securities Market Notice
9th Oct 201712:13 pmRNSResult of General Meeting & Completion of Placing
21st Sep 20177:00 amRNSPlacing to raise EUR 15m
4th Sep 20177:00 amRNSInterim Results
31st Aug 20177:00 amRNSAttendance at Rodman & Renshaw Conference
30th Aug 20177:00 amRNSSenior Management Appointment
23rd Aug 20178:30 amRNSNotice of Results
25th Jul 20177:00 amRNSHighly positive long-term study results - Lojuxta
25th May 201711:49 amRNSResult of AGM
25th May 20177:00 amRNSAGM Statement
27th Apr 20177:00 amRNSStudy Results of Real-World Experience of Lojuxta

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.